Cite
Hézode C, Alric L, Brown A, et al. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 2015;21(3):195-205doi: 10.3851/IMP2985.
Hézode, C., Alric, L., Brown, A., Hassanein, T., Rizzetto, M., Buti, M., Bourlière, M., Thabut, D., Molina, E., Rustgi, V., Samuel, D., McPhee, F., Liu, Z., Yin, P. D., Hughes, E., Treitel, M. (2015). Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antiviral therapy, 21(3), 195-205. https://doi.org/10.3851/IMP2985
Hézode, Christophe, et al. "Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)." Antiviral therapy vol. 21,3 (2015): 195-205. doi: https://doi.org/10.3851/IMP2985
Hézode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, Bourlière M, Thabut D, Molina E, Rustgi V, Samuel D, McPhee F, Liu Z, Yin PD, Hughes E, Treitel M. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 2015 Aug 27;21(3):195-205. doi: 10.3851/IMP2985. Epub 2015 Aug 27. PMID: 26313445.
Copy
Download .nbib